检索结果-南通市图书馆

Expert consensus on the procedure of interventional diagnosis and treatment of cancer patients during the COVID-19 epidemic

在线全文

学校读者我要写书评

暂无评论

Journal of Interventional Medicine 2020年第2期3卷 61-64页

作者：无 Tianshi Lyu Li Song Long Jin Yinghua Zou Interventional Oncology Branch of china anti-cancer association Department of Interventional Radiology and Vascular Surgery Peking University First HospitalBeijing100034China Department of Interventional Radiology Beijing Friendship HospitalCapital Medical UniversityBeijing100050China

Since December 2019, coronavirus disease(COVID-19) has spread rapidly from Wuhan, Hubei province, to other regions of china. To reduce and prevent cross-over infections in the interventional diagnosis and treatment of tumor patients. The Interventional Oncology Branch of the china anti-cancer association organized specialists to compile the corresponding expert consensus. The consensus summarizes the critical points for COVID-19 prevention, focusing on the management of outpatients, inpatients, and interventional operating room in this particular time.

关键词： Novel coronavirus Pneumonia Intervention Expert consensus

在线全文

学校读者我要写书评

暂无评论

子宫颈癌手术技术指南（2024年版）

中国实用妇科与产科杂志 2024年第12期 1217-1225页

作者： Cervical cancer Committee of china anti-cancer association 中国抗癌协会宫颈癌专业委员会

子宫颈癌手术治疗的发展经历了多个阶段，涵盖了手术范围与方法技术的演进。子宫颈癌手术探索始于1878年，德国医生Freund首先采用经腹子宫切除术治疗子宫颈癌[1]。1898年奥地利医生Wertheim首次将经腹广泛性子宫切除术进行大宗报道，... 详细信息

子宫颈癌手术治疗的发展经历了多个阶段，涵盖了手术范围与方法技术的演进。子宫颈癌手术探索始于1878年，德国医生Freund首先采用经腹子宫切除术治疗子宫颈癌[1]。1898年奥地利医生Wertheim首次将经腹广泛性子宫切除术进行大宗报道，该术式操作安全，将患者手术死亡率降至10%，被称为Wertheim术式[2]。

关键词：子宫颈癌手术治疗指南

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma(2022 version)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2023年第7期11卷 1553-1564页

作者： Han Wang Jun Chen Xin Zhang Xia Sheng Xiao-Yan Chang Jie Chen Min-Shan Chen Hui Dong Guang-Jie Duan He-Ping Hu Zhi-Yong Huang Wei-Dong Jia Xiao-Qing Jiang Dong Kuang Shan-Shan Li Zeng-Shan Li Chang-Li Lu Shu-Kui Qin Xue-Shan Qiu Li-Juan Qu Chun-Kui Shao Feng Shen Guo-Ming Shi Su-Sheng Shi Yu-Jun Shi Hui-Chuan Sun Xiao-Dong Teng Bin Wang Zhan-Bo Wang Tian-Fu Wen Jia-Mei Yang Qiao-Qiao Yang Sheng-Long Ye Hong-Fang Yin Zhen-Gang Yuan Jing-Ping Yun Feng-Lin Zang Hong-Qi Zhang Li-Hong Zhang Jing-Min Zhao Jian Zhou Wei-Xun Zhou Jia Fan Xiao-Ping Chen Wan Yee Lau Yuan Ji Wen-Ming Cong Chinese Society of Liver cancer of Chinese anti-cancer association Digestive Disease Group of Chinese Society of Pathology,Chinese Medical association Chinese Society of Pathology of Chinese anti-cancer association Hepatic Surgery Group of Chinese Society of Surgery,Chinese Medical association Biliary Tract Tumor Committee of china anti-cancer association Chinese Society of Clinical Oncology IDepartment of Pathology Eastern Hepatobilary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology the Affiliated Drum Tower HospitalNanjing University Medical SchoolNanjingJiangsuChina Department of Pathology Zhongshan HospitalFudan UniversityShanghaiChina Department of Pathology Minhang HospitalFudan Uni-versityShanghaiChina Department of Pathology Peking Union Medical College HospitalChinese Academy of Medical Sci-ences and Peking Union Medical CollegeBeijingChina Department of Liver Surgery Sun Yat-Sen University Cancer CenterGuangzhouGuangdongChina Department of Pathology The First Affiliated HospitalArmy Medical UniversityChongqingChina Department of Hepatobiliary Medicine Eastern Hepatobiliary Surgery HospitalNaval Medical UniversityShanghaiChina Hepatic Surgery Center Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWu-hanHubeiChina Department of General Surgery The First Affliated Hospital of USTCDivision of Life Science and Medi-cineUniversity of Science and Technology of ChinaHefeiAnhuiChina Department of Biliary Surgery I Eastern Hepatobil-iary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Department of Pathology The First Afiliated Hospital of Zhengzhou UniversityZhengzhou UniversityZhengzhouHenanChina Department of Pathology Xijing Hospi-talAir Force Medical UniversityXi'anShaanxiChina Department of Pathology West China HospitalSichuan UniversityChengduSichuanChina cancer Center of Jinling Hospital Nanjing University of Chinese MedicineNanjingJiangsuChina Department of Pathology The First Affiliated HospitalChina Medical UniversityShenyangLiaoningChina Department of Pathology The 900 Hospital of the Chinese People's Liberation Army Joint Logistics TeamFuzhouFujianChina Department of Pathology The Third Affiliated HospitalSun Yat-Sen UniversityGuangz

Intrahepatic cholangiocarcinoma(iCCA)can originate from the large bile duct group(segment bile ducts and area bile ducts),small bile duct group(septal bile ducts and interlobular bile ducts),and terminal bile duct group(bile ductules and canals of Hering)of the intrahepatic biliary tree,which can be histopathological corresponding to large duct type iCCA,small duct type iCCA and iCCA with ductal plate malformation pattern,and cholangiolocarcinoma,*** challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies,tissue structures,growth patterns,invasive behaviors,immunophenotypes,molecular mutations,and surgical *** these reasons,this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA,mainly based on the 5th edition of the World Health Organization Classification of Tumours of the Digestive System.

关键词： Intrahepatic cholangiocarcinoma Pathology Histological type Immunohistochemistry Molecular variation

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国乳腺癌筛查与早期诊断指南

中国癌症杂志 2022年第4期32卷 363-372页

作者：中国抗癌协会乳腺癌专业委员会吴炅不详复旦大学附属肿瘤医院

中国抗癌协会乳腺癌专业委员会于2020年4月—2021年11月,采用改编《欧盟委员会乳腺癌指南》的方法,编写制定了《中国乳腺癌筛查和早期诊断指南》(后文简称指南)。指南遵循GRADE系统方法,共包括50条推荐意见和5条专家共识,涉及乳腺癌的... 详细信息

中国抗癌协会乳腺癌专业委员会于2020年4月—2021年11月,采用改编《欧盟委员会乳腺癌指南》的方法,编写制定了《中国乳腺癌筛查和早期诊断指南》(后文简称指南)。指南遵循GRADE系统方法,共包括50条推荐意见和5条专家共识,涉及乳腺癌的筛查、早期诊断、复发风险基因检测以及筛查项目中的沟通和培训等专业领域。指南推荐意见的形成考虑了目前最佳循证医学证据、中国女性群体的价值观念与偏好、成本和资源配置等因素。在应用本指南推荐的筛查和诊断技术时,应结合各地实际情况。

关键词：乳腺癌筛查早期诊断指南

在线全文

学校读者我要写书评

暂无评论

胸部肿瘤经皮穿刺活检中国专家共识

中华介入放射学电子杂志 2018年第3期6卷 188-194页

作者：无郭志史红中国抗癌协会肿瘤介入学专业委员会中国抗癌协会肿瘤介入学专业委员会青委会天津医科大学肿瘤医院介入治疗科中华医学会杂志社

活检应用于胸部疾病的诊断已有百余年历史。根据取材方法不同,胸部肿瘤活检可分为经支气管镜活检、经皮穿刺活检、经胸腔镜活检和开胸性活检。胸部肿瘤经皮穿刺活检(percutaneous transthoracic needle biopsy,PTNB)是在影像设备引导下... 详细信息

活检应用于胸部疾病的诊断已有百余年历史。根据取材方法不同,胸部肿瘤活检可分为经支气管镜活检、经皮穿刺活检、经胸腔镜活检和开胸性活检。胸部肿瘤经皮穿刺活检(percutaneous transthoracic needle biopsy,PTNB)是在影像设备引导下完成的活检操作,随着影像技术设备的不断更新,经皮穿刺活检的临床应用范围不断拓展,从最早的病理诊断扩大到组织亚型分类、基因诊断,临床需求日益增多。与此同时,提高我国专业技术人员对经皮穿刺胸部肿瘤活检的认识,规范其操作流程,加强围手术期管理显得尤为重要。

关键词：经皮穿刺活检胸部肿瘤影像设备引导专家中国支气管镜活检 needle biopsy

中国肿瘤整合诊治指南-肝癌(2022精简版)

在线全文

学校读者我要写书评

暂无评论

中国肿瘤临床 2022年第17期49卷 865-873页

作者：中国抗癌协会肝癌专业委员会陈敏山不详中山大学肿瘤防治中心

肝癌是我国第5位常见恶性肿瘤及第2位肿瘤致死病因,严重威胁我国人民的生命健康。现有的国际诊疗指南在临床实践中无法兼顾我国肝癌的疾病背景、诊疗资源的地区差异、肿瘤治疗的社会价值等,难以实现个体化诊疗决策。中国抗癌协会肝癌专... 详细信息

肝癌是我国第5位常见恶性肿瘤及第2位肿瘤致死病因,严重威胁我国人民的生命健康。现有的国际诊疗指南在临床实践中无法兼顾我国肝癌的疾病背景、诊疗资源的地区差异、肿瘤治疗的社会价值等,难以实现个体化诊疗决策。中国抗癌协会肝癌专业委员会组织业内专家依据循证医学方法制定了《中国肿瘤整合诊治指南-肝癌》,以“防-筛-诊-治-康”为基础,内容涉及肝癌的流行病学、筛查、影像学检查、病理学评估、外科治疗、介入治疗、系统性药物治疗、放疗和中医药治疗等多学科整合治疗手段、全程康复管理等。希望本指南能够为临床医师的临床诊疗提供最佳的、有效的意见参考,从而使我国肝癌患者达到最佳的治疗效果。

关键词：肝癌整合诊治指南

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of Chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of Chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of Chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of china anti-cancer association(CACA) Chinese Society of Hematology of Chinese Medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

局部进展期胃癌规范化淋巴结清扫范围中国专家共识(2022版)

在线全文

学校读者我要写书评

暂无评论

中华胃肠外科杂志 2022年第4期25卷 277-283页

作者：中国抗癌协会胃癌专业委员会季加孚梁寒徐惠绵柯彬不详北京大学肿瘤医院天津医科大学肿瘤医院中国医科大学附属第一医院

局部进展期胃癌(LAGC)应进行以手术为主的综合治疗。规范化的淋巴结清扫,是胃癌根治术的关键。随着国内外相关系列临床研究的证实,将D2根治术作为LAGC的标准术式已达成全球共识。合理的淋巴结清扫,对改善患者的预后和减少手术的并发症,... 详细信息

局部进展期胃癌(LAGC)应进行以手术为主的综合治疗。规范化的淋巴结清扫,是胃癌根治术的关键。随着国内外相关系列临床研究的证实,将D2根治术作为LAGC的标准术式已达成全球共识。合理的淋巴结清扫,对改善患者的预后和减少手术的并发症,具有重要的临床意义。而选择性地进行扩大淋巴结清扫,也可使部分患者获益。但是,对于合理的D2淋巴结清扫范围,目前仍然存在争议。为了指导我国LAGC淋巴结清扫的规范实施,中国抗癌协会胃癌专业委员会组织国内胃癌治疗领域的专家,对LAGC淋巴结清扫的关键内容进行多次讨论,并对争议问题进行投票,共同制定了《局部进展期胃癌规范化淋巴结清扫范围中国专家共识(2022版)》。希望本共识能为广大临床医师提供参考,进而提高我国LAGC的诊疗水平。

关键词：胃肿瘤根治性胃切除术淋巴结清扫专家共识

肿瘤类器官诊治平台的质量控制标准中国专家共识(2022年版)

在线全文

学校读者我要写书评

暂无评论

中国癌症杂志 2022年第7期32卷 657-668页

作者：中国抗癌协会肿瘤多学科诊疗专业委员会中国抗癌协会肿瘤内分泌专业委员会邹冬玲赵宏余佳赵冰王海霞不详重庆大学附属肿瘤医院妇科肿瘤中心中国医学科学院肿瘤医院肝胆外科中国医学科学院基础医学研究所科研处复旦大学中国医学科学院基础医学研究所重庆大学附属肿瘤医院

近年来,类器官技术的发展为开发新的、更接近真实病理生理学状态的人类癌症模型开辟了新途径。源自患者的肿瘤类器官保留了原始肿瘤的组织病理学特征、遗传特征和分子生物学特征等表型,不仅可作为识别和测试新型抗癌药物的优良模型,也... 详细信息

近年来,类器官技术的发展为开发新的、更接近真实病理生理学状态的人类癌症模型开辟了新途径。源自患者的肿瘤类器官保留了原始肿瘤的组织病理学特征、遗传特征和分子生物学特征等表型,不仅可作为识别和测试新型抗癌药物的优良模型,也可通过肿瘤类器官的药物敏感性检测反馈患者的临床反应,为肿瘤患者的个体化精准治疗提供可靠的依据。然而,与传统的组织样本库相比,活体类器官生物库的建立需要更严格的质量控制和更高水平的技术标准。随着类器官研究的不断深入,肿瘤类器官已广泛覆盖多种实体瘤,类器官技术亦在2017年被评为生命科学领域年度技术,但国内对肿瘤类器官构建、鉴定及药物敏感性检测尚无质量控制标准,同时亦缺乏肿瘤类器官用于精准治疗的专家共识。因此,根据全球范围内多个团队基于患者来源的肿瘤类器官的药物敏感性检测在肿瘤精准治疗中已发表的研究数据,中国抗癌协会肿瘤多学科诊疗专业委员会、中国抗癌协会肿瘤内分泌专业委员会针对肿瘤类器官药物敏感性检测的临床应用与质量控制制订了《肿瘤类器官诊治平台的质量控制标准中国专家共识(2022年版)》,希望通过本共识,提高中国临床工作者及医学研究者对于类器官药物敏感性检测的认识,规范类器官诊治平台的质量控制,指导类器官药物敏感性检测在国内肿瘤精准治疗方案选择中的临床应用。本共识将根据未来开展的基于类器官的各项研究成果定期更新。

关键词：类器官诊治平台质量控制共识肿瘤